Daxor Co. (NASDAQ:DXR) Short Interest Update

Daxor Co. (NASDAQ:DXR) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 12,100 shares, a decline of 8.3% from the January 15th total of 13,200 shares. Based on an average daily trading volume, of 16,500 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.6% of the shares of the stock are sold short.

Institutional Trading of Daxor

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC grew its position in shares of Daxor Co. (NASDAQ:DXR) by 34.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 at the end of the most recent quarter. 1.34% of the stock is owned by institutional investors and hedge funds.

Daxor Trading Up 0.7 %

Shares of DXR opened at $7.23 on Wednesday. The business’s 50-day moving average price is $7.92 and its 200-day moving average price is $8.61. Daxor has a twelve month low of $6.55 and a twelve month high of $10.00.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.